+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Statin discontinuation: an underestimated risk?

Statin discontinuation: an underestimated risk?

Current Medical Research and Opinion 24(11): 3059-3062

Statin treatment is essential for the prevention of vascular disease. Despite the established benefits of statins, discontinuation of these agents is frequent. Whether statin discontinuation leads to adverse outcomes is still debated and the most convincing evidence is mainly restricted to patients who experienced an acute vascular event. It is important to establish if this phenomenon extends to other populations, like those without vascular disease but with a high calculated risk. Overall, it appears that even a brief discontinuation of statins might be harmful. Therefore, statin treatment should not be interrupted except if there is a very good reason. Moreover, patients should be instructed as to why they must adhere to their medication. Adherence should be monitored regularly.

(PDF emailed within 0-6 h: $19.90)

Accession: 055911065

Download citation: RISBibTeXText

PMID: 18826752

DOI: 10.1185/03007990802469102

Related references

Patient characteristics and statin discontinuation-related factors during treatment of hypercholesterolemia: an observational non-interventional study in patients with statin discontinuation (STAY study). Turk Kardiyoloji Dernegi Arsivi 44(1): 53-64, 2016

Managing the underestimated risk of statin-associated myopathy. International Journal of Cardiology 159(3): 169-176, 2013

Statin-related muscle complaints: an underestimated risk. Cardiovascular Drugs and Therapy 19(6): 379-381, 2006

Statin discontinuation in high-risk patients: a systematic review of the evidence. Current Pharmaceutical Design 17(33): 3669-3689, 2013

Treatment of statin adverse effects with supplemental Coenzyme Q10 and statin drug discontinuation. Biofactors 25(1-4): 147-152, 2006

Risk factors for discontinuation of statin medications: Evidence from a large national pharmacy claims database. 2007

Predictors of Statin Adherence, Switching, and Discontinuation in the USAGE Survey Understanding Statin Use in America and Gaps in Patient Education. Journal of Clinical Lipidology 7(3): 245-246, 2013

Statin discontinuation and risk of acute myocardial infarction in patients with rheumatoid arthritis: a population-based cohort study. Annals of the Rheumatic Diseases 70(6): 1020-1024, 2011

Ability of low antihypertensive medication adherence to predict statin discontinuation and low statin adherence in patients initiating treatment after a coronary event. American Journal of Cardiology 114(6): 826-831, 2014

Statin-induced muscular problems are underestimated. Ugeskrift for Laeger 172(16): 1235; Author Reply 1235, 2010

Autoimmune necrotizing myopathy after statin discontinuation. Bmj Case Reports 12(5), 2019

Discontinuation of statin treatment in stroke patients. Stroke 37(10): 2640-2643, 2006

Platelet hyperactivity after statin treatment discontinuation. Thrombosis and Haemostasis 90(3): 476-482, 2003

Statin discontinuation: counterbalancing the benefits with the potential risks. Archives of Medical Science 7(6): 1076-1077, 2012

Reinitiation of Statin Therapy After Discontinuation: A Meta-analysis. Mayo Clinic Proceedings 93(5): 666-668, 2018